Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche to acquire Telavant for $7.1b.

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 23, 2023 9:43am

157 Views

Post# 35696012

RE:Roche to acquire Telavant for $7.1b.

Roche to acquire Telavant Holdings experimental IBD drug known as RVT-3101 for $7.1 billion.

Roche said that it would buy Telavant Holdings, a vehicle in which Roivant and Pfizer have placed the rights to develop, manufacture and commercialize the experimental drug known as RVT-3101 in the United States and Japan.

https://www.reuters.com/markets/deals/roche-buys-telavant-holdings-71-billion-2023-10-23/

<< Previous

Bullboard Posts

Next >>

3 Mid-Sized Stocks to Consider This Season